Cargando…

A novel adaptive trial design: randomised evaluation of molecular guided therapy for diffuse large b-cell lymphoma with bortezomib (REMODL-B) with two interim analyses to explore safety and efficacy

Detalles Bibliográficos
Autores principales:	Maishman, Tom, Stanton, Louise, Davies, Andy, Barrans, Sharon, Worrillow, Lisa, Mamot, Christoph, Care, Matt, Immins, Tikki, Hamid, Debbie, McMillan, Andrew, Fields, Paul, Jack, Andrew, Johnson, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980503/ http://dx.doi.org/10.1186/1745-6215-14-S1-O77

Ejemplares similares

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
por: Davies, Andrew, et al.
Publicado: (2019)

Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up
por: Davies, Andrew J., et al.
Publicado: (2023)

A Microarray Platform-Independent Classification Tool for Cell of Origin Class Allows Comparative Analysis of Gene Expression in Diffuse Large B-cell Lymphoma
por: Care, Matthew A., et al.
Publicado: (2013)

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy
por: Sha, Chulin, et al.
Publicado: (2019)

A Novel Approach to Overcome Movement Artifact When Using a Laser Speckle Contrast Imaging System for Alternating Speeds of Blood Microcirculation
por: Bahadori, Shayan, et al.
Publicado: (2017)

A review of wearable motion tracking systems used in rehabilitation following hip and knee replacement
por: Bahadori, Shayan, et al.
Publicado: (2018)

Transferring genomics to the clinic: distinguishing Burkitt and diffuse large B cell lymphomas
por: Sha, Chulin, et al.
Publicado: (2015)

What Is Important to the Younger Person (≤50 Years) When Having a Total Hip Arthroplasty: A Systematic Literature Review
por: Mew, Louise, et al.
Publicado: (2023)

Interim results from the Age Trial
por: Moss, S, et al.
Publicado: (2004)

Plantar heel pain: an update of its aetiology and diagnosis
por: Landorf, Karl B, et al.
Publicado: (2013)

Self-Management of Hip Osteoarthritis Five Years After a Cycling and Education Treatment Pathway
por: Wainwright, Thomas W., et al.
Publicado: (2020)

Understanding the Patient Perspective When Designing Future Rehabilitation Interventions after Hip or Knee Replacement Surgery—A Patient and Public Involvement Exercise
por: Gavin, James P., et al.
Publicado: (2023)

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
por: Powderly, John, et al.
Publicado: (2015)

Health system challenges in implementing universal health coverage: Asian perspectives and experiences
por: Pang, Tikki, et al.
Publicado: (2014)

Bortezomib Induced Hepatitis B Reactivation
por: Hussain, Salwa, et al.
Publicado: (2014)

Ultrasound guided corticosteroid injection for plantar fasciitis: a randomised controlled trial
por: McMillan, Andrew, et al.
Publicado: (2011)

A cycling and education intervention for the treatment of hip osteoarthritis: A quality improvement replication programme
por: Wainwright, Thomas W, et al.
Publicado: (2020)

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial
por: Davies, Andrew, et al.
Publicado: (2020)

Interim reports for data monitoring committee review vs final reports for regulatory filing
por: Kim, KyungMann
Publicado: (2011)

73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks
por: VanderVeen, Laurie, et al.
Publicado: (2021)

Subtle structural abnormalities in genotype positive phenotype ‘negative’ patients with pre-clinical hypertrophic cardiomyopathy (HCM): a blinded, controlled cardiovascular magnetic resonance (CMR) study
por: Deva, Djeven, et al.
Publicado: (2012)

The prognosis of MYC translocation positive diffuse large B‐cell lymphoma depends on the second hit
por: Clipson, Alexandra, et al.
Publicado: (2015)

Does aquatic exercise improve commonly reported predisposing risk factors to falls within the elderly? A systematic review
por: Martínez-Carbonell Guillamón, Eduardo, et al.
Publicado: (2019)

A 1RM Strengthening and Exercise Programme for the Treatment of Knee Osteoarthritis: A Quality-Improvement Study
por: Creasey, James, et al.
Publicado: (2023)

S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY
por: Carpenedo, Monica, et al.
Publicado: (2023)

SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity
por: Care, Matthew A., et al.
Publicado: (2014)

8. The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)
por: Boutry, Céline, et al.
Publicado: (2020)

123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Pappas, Peter G, et al.
Publicado: (2021)

S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
por: Anderson, Alan, et al.
Publicado: (2023)

Interim results of a clinical trial using oncolytic virotherapy in Kaposi's sarcoma-associated herpesvirus (KSHV) associated-Multicentric Castleman's Disease (MCD)
por: Yarchoan, R, et al.
Publicado: (2009)

P056 Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

Improved in-vivo cardiac DTI using optimal b-values
por: Scott, Andrew D, et al.
Publicado: (2014)

S139: INTERIM ANALYSIS OF A REGISTRATION ENABLING STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) A CD123-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
por: Pemmaraju, Naveen, et al.
Publicado: (2023)

Incremental predictive value of deep crypts in the basal inferoseptum in the setting of hypertrophic cardiomyopathy
por: Deva, Djeven P, et al.
Publicado: (2013)

P057 All- cause mortality in patients with invasive Candidiasis or candidemia from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines
por: Chan, Wei Yee, et al.
Publicado: (2021)

Efficacy and safety of peginterferon alfa-2a + RBV in cHCV/HIV- vs cHCV-infected patients: interim analysis of a multicenter German cohort
por: Baumgarten, A, et al.
Publicado: (2010)

B cell directed cytokines
por: Lipsky, Peter E
Publicado: (2011)

Characterizing the role of the alternative NF-κB pathway in diffuse large B-cell lymphoma
por: Ito, Daisuke, et al.
Publicado: (2013)

Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
por: Kagdi, Huseini, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_46i342ek3fti6g58sjbvq4tj2v